Destination

2025-03-24

Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.

Read more...

[...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination

2025-03-07

Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]

Match Score: 172.53

Destination

2025-04-29

Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 158.38

Destination

2025-01-03

The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 156.07

Destination

2025-05-01

VR is helping to make daunting medical treatments more bearable for patients

Stanley Johnson is not a fan of needles. The 67-year-old Air Force veteran has endured his fair share of pokes over the years, but when it was decided that IV infusions would be the best course of act [...]

Match Score: 153.54

Destination

2025-03-27

Wegovy sales took a hit this year. Novo's CEO blames off-brand competition

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giantâ [...]

Match Score: 146.83

thenextweb

2025-01-10

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 142.99

Destination

2025-04-02

Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 138.91

Destination

2025-03-28

Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup

Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection [...]

Match Score: 128.22

Destination

2025-03-31

Eli Lilly and Novo Nordisk are tackling heart health next

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read more... [...]

Match Score: 111.33